Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Columbia Labs U.S. plans

This article was originally published in The Tan Sheet

Executive Summary

Women's products Advantage-S spermicidal contraceptive, RepHresh Vaginal Gel to be commercialized in U.S. beginning this quarter under agreement with Livingston, N.J.-based Quintiles Transnational. Firm's Innovex commercialization unit will provide 55 sales reps on a three-year, pay-for-service basis. Additionally, PharmaBio Development, Quintiles' strategic investment group, has purchased $5.5 mil. in Columbia Labs stock and will invest $4.5 mil. in return for 5% royalty on U.S. net sales of Columbia's women's portfolio. Sales efforts for Advantage-S, RepHresh, several Rx drugs will be targeted to OB/GYNs and are expected to significantly expand brand exposure...

You may also be interested in...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts